Preferred Name | palbociclib | |
Synonyms |
Ibrance PD-0332991 PD 0332991 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one PD0332991 |
|
ID |
http://purl.bioontology.org/ontology/MESH/C500026 |
|
altLabel |
Ibrance PD-0332991 PD 0332991 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one PD0332991 |
|
cui |
C3853822 C1568660 C3883373 |
|
HM |
D011725 D010879 |
|
II |
D018844/Q000037 |
|
Inverse of RB |
G9ZF61LE7G 0 |
|
isa | ||
LT |
TRD |
|
Mapped to | ||
MDA |
20050428 |
|
MeSH Frequency |
854 |
|
MMR |
20150205 |
|
notation |
C500026 |
|
PA |
D047428 D000970 |
|
prefLabel |
palbociclib |
|
SC |
1 |
|
Scope Statement |
has antineoplastic activity; specific inhibitor of cyclin-dependent kinases 4 & 6; structure in first source |
|
SRC |
Mol Cancer Ther 2004 Nov;3(11):1427-38 |
|
TERMUI |
T000867026 T638362 T000874759 T639746 T639748 T639747 |
|
TH |
NLM (2005) NLM (2015) USAN (19XX) INN (19XX) FDA SRS (2015) NLM (2014) |
|
tui |
T109 T121 |
Create mapping